ERBB2 and neoplasm: In a within-patient comparison, Sestak et al. found that the signatures providing the most useful prognostic information in postmenopausal, node-negative patients with ER-positive/HER2 negative tumours were Prosigna® (ROR; HR 2.56) and EndoPredict® (EPclin; HR 2.14).